Improving target cell specificity using a novel monovalent bispecific IgG design.
MAbs
; 7(2): 377-89, 2015.
Article
en En
| MEDLINE
| ID: mdl-25621507
Palabras clave
ADCC, antibody-dependent cell-mediated cytotoxicity; Biotechnology; CDR, complementarity determining region; CH1, 2 and 3-heavy chain constant domain 1, 2 and 3; CL-, light chain constant domain; DSC-differential scanning calorimetry; E:T, ratio of effector to target cells; EGFR; EGFR, epidermal growth factor receptor; FcRn, neonatal Fc receptor; FcγR, receptor for IgG Fc; HER2; IGFR, insulin like growth factor receptor; IL-6, interleukin 6; IgG, Immunoglobulin G; PNGase, protein N-glycanase; Q1q, first component of complement 1; RAGE, receptor for advanced glycosylation; antibody engineering; bispecific antibody; cancer; disulfide; mAbs, monoclonal antibodies; multi-targeting
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Inmunoglobulina G
/
Anticuerpos Biespecíficos
/
Cetuximab
/
Trastuzumab
/
Afinidad de Anticuerpos
Límite:
Humans
Idioma:
En
Revista:
MAbs
Asunto de la revista:
ALERGIA E IMUNOLOGIA
Año:
2015
Tipo del documento:
Article
